Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is ResMed Inc. (RMD) Halal?

PASS

ResMed Inc. · NYSE: RMD · Healthcare

The short answer

Yes -- ResMed Inc. (RMD) passes this Shariah stock screen at all three gates. Per its own FY2025 10-K (fiscal year ended June 30, 2025, filed August 8, 2025), ResMed's core business is medical devices and digital health -- CPAP and flow-generator devices, ventilation devices, diagnostic products, masks and accessories, plus cloud-based connected-care software and SaaS residential-care platforms -- with no conventional banking, insurance, alcohol, gambling, pork, tobacco or weapons segments, so the business-activity gate passes. Its separately disclosed interest income of $4.1M for FY2025 is about 0.08% of its $5,146.3M in net revenue, under the 5% non-compliant income ceiling. Its debt screen passes: $851.8M of short-term and long-term debt plus operating lease liabilities is about 2.63% of its ~$32.38B market cap ($221.15, latest close retrieved October 2, 2026), below the ~33% ceiling. Third parties agree: Zoya describes RMD as Shariah-compliant, and Musaffa classifies it as halal (October 2026); no ShariaPortfolio coverage of RMD was found -- honestly reported, not invented.

Gate 1 — Business activity: PASS

ResMed Inc. (NYSE: RMD), based in San Diego, California, describes itself in its FY2025 10-K (fiscal year ended June 30, 2025, filed August 8, 2025) as a global leader in digital health and cloud-connected medical devices. Through its subsidiaries it designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea -- the business it started in 1989 when it commercialised CPAP treatment. Its range includes CPAP and other flow-generator devices, ventilation devices, diagnostic products, mask systems and accessories, plus cloud-based software for connected care and SaaS residential-care platforms supporting home medical equipment providers and caregivers. It reports two revenue lines: Sleep and Breathing Health products ($4,504.9M) and Residential Care Software ($641.4M) for FY2025. Business screen (factual, from the filing): nothing in Item 1 involves conventional banking, lending, insurance, alcohol, gambling, pork, tobacco or weapons. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per ResMed's FY2025 10-K balance sheet (June 30, 2025), interest-bearing debt was $851.8M -- long-term debt of $658.4M (revolving credit, term credit and senior notes per Note 8), short-term debt of $9.9M, and operating lease liabilities of $183.5M ($30.5M current and $153.0M non-current, Note 9). Trade payables, accrued expenses and deferred revenue are operating liabilities and are not counted as debt. Against a market cap of about $32.38B ($221.15 latest close retrieved October 2, 2026; 146,414,839 shares outstanding per the 10-K cover), debt divided by market cap is about 2.63%, far below the ~33% ceiling. Cash and cash equivalents of $1,209.5M are about 3.74% of market cap, and no separate short-term investments line is disclosed. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

ResMed's FY2025 10-K income statement reports net revenue of $5,146.3M and interest income (expense), net of $4.1M -- net interest income, i.e. interest earned on cash balances (aided by lower debt levels after revolving credit repayments). The separately disclosed interest line of $4.1M is about 0.08% of revenue, far below the 5% non-compliant income ceiling. Cash interest paid for the year ($28.4M) is a financing outflow, not income. Gate 3 passes. Facts only.

Key figures used

Frequently asked questions

What does ResMed do?

ResMed Inc. (NYSE: RMD), based in San Diego, California, describes itself in its FY2025 10-K (fiscal year ended June 30, 2025, filed August 8, 2025) as a global leader in digital health and cloud-connected medical devices. Through its subsidiaries it designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea -- the business it started in 1989 when it commercialised CPAP treatment. Its products include CPAP and other flow-generator devices, ventilation devices, diagnostic products, mask systems and accessories, plus cloud-based software for connected care and SaaS residential-care platforms supporting home medical equipment providers and caregivers. Revenue is split into Sleep and Breathing Health products ($4,504.9M) and Residential Care Software ($641.4M) for FY2025.

Why does ResMed pass the business-activity screen?

ResMed passes the business-activity gate. Its core business per the FY2025 10-K is medical devices and digital health -- CPAP equipment, ventilation devices, diagnostic products, masks and accessories, plus connected-care software and SaaS platforms for residential care -- none of which is conventional banking, lending, insurance, alcohol, gambling, pork, tobacco or weapons. It reports two revenue lines, Sleep and Breathing Health products and Residential Care Software, and nothing in Item 1 describes any non-compliant segment. This is a factual screen, not a religious ruling -- consult a qualified scholar for personal rulings.

What is ResMed's interest-bearing debt ratio?

Per ResMed's FY2025 10-K balance sheet (June 30, 2025), interest-bearing debt was $851.8M -- long-term debt of $658.4M (revolving credit, term credit and senior notes per Note 8) plus short-term debt of $9.9M plus operating lease liabilities of $183.5M ($30.5M current and $153.0M non-current, Note 9). Trade payables, accrued expenses and deferred revenue are operating liabilities and are not counted as debt. Against a market cap of about $32.38B ($221.15 latest close retrieved October 2, 2026; 146,414,839 shares outstanding per the 10-K cover), debt divided by market cap is about 2.63% -- far below the ~33% ceiling. Cash and cash equivalents of $1,209.5M are about 3.74% of market cap, and no separate short-term investments line is disclosed.

What is ResMed's non-compliant income ratio?

ResMed's FY2025 10-K income statement reports net revenue of $5,146.3M and interest income (expense), net of $4.1M (net interest income -- interest earned on cash balances, aided by lower debt levels after revolving credit repayments). The separately disclosed interest line of $4.1M is about 0.08% of revenue, far below the 5% non-compliant income ceiling. Cash interest paid for the year was $28.4M, which is a financing outflow, not income. Gate 3 passes.

Do Zoya, Musaffa, or ShariaPortfolio cover ResMed?

Zoya covers RMD and describes it as Shariah-compliant and therefore considered halal to invest in, based on the data in Resmed's most recent financial reports (zoya.finance/stocks/rmd; the page's displayed assessment date was blank when accessed in October 2026). Musaffa covers RMD and classifies Resmed Inc as halal as of October 2026 under its AAOIFI methodology (musaffa.com/stock/RMD/). No ShariaPortfolio (spscreener.mxcorporate.com) coverage of RMD was found through public web search. All coverage statements are reported honestly as found, not invented.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).